CN102639518B - 新型苯酚衍生物 - Google Patents

新型苯酚衍生物 Download PDF

Info

Publication number
CN102639518B
CN102639518B CN201080042866.9A CN201080042866A CN102639518B CN 102639518 B CN102639518 B CN 102639518B CN 201080042866 A CN201080042866 A CN 201080042866A CN 102639518 B CN102639518 B CN 102639518B
Authority
CN
China
Prior art keywords
dihydro
benzothiazole
reduced pressure
under reduced
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080042866.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN102639518A (zh
Inventor
小桥精一
雨田淳一郎
宫田幸帆
井上助
芦泽直树
松本浩二
谷口哲也
岩永崇
永田治
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujiyakuhin Co Ltd
Original Assignee
Fujiyakuhin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43826265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102639518(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fujiyakuhin Co Ltd filed Critical Fujiyakuhin Co Ltd
Publication of CN102639518A publication Critical patent/CN102639518A/zh
Application granted granted Critical
Publication of CN102639518B publication Critical patent/CN102639518B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CN201080042866.9A 2009-09-30 2010-09-29 新型苯酚衍生物 Active CN102639518B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009-227402 2009-09-30
JP2009227402A JP5325065B2 (ja) 2009-09-30 2009-09-30 新規フェノール誘導体
PCT/JP2010/066925 WO2011040449A1 (ja) 2009-09-30 2010-09-29 新規フェノール誘導体

Publications (2)

Publication Number Publication Date
CN102639518A CN102639518A (zh) 2012-08-15
CN102639518B true CN102639518B (zh) 2015-03-25

Family

ID=43826265

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080042866.9A Active CN102639518B (zh) 2009-09-30 2010-09-29 新型苯酚衍生物

Country Status (23)

Country Link
US (1) US8367843B2 (enExample)
EP (1) EP2484669B1 (enExample)
JP (1) JP5325065B2 (enExample)
KR (1) KR101647174B1 (enExample)
CN (1) CN102639518B (enExample)
AU (1) AU2010301675B2 (enExample)
BR (1) BR112012007069B1 (enExample)
CA (1) CA2775309C (enExample)
DK (1) DK2484669T3 (enExample)
ES (1) ES2549603T3 (enExample)
HU (1) HUE026007T2 (enExample)
IL (1) IL218519A (enExample)
IN (1) IN2012DN02551A (enExample)
MX (1) MX2012003392A (enExample)
MY (1) MY160394A (enExample)
NZ (1) NZ598582A (enExample)
PH (1) PH12012500643A1 (enExample)
PL (1) PL2484669T3 (enExample)
PT (1) PT2484669E (enExample)
RU (1) RU2536689C2 (enExample)
TW (1) TWI461195B (enExample)
WO (1) WO2011040449A1 (enExample)
ZA (1) ZA201201895B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5851802B2 (ja) 2011-03-30 2016-02-03 富士重工業株式会社 炭素繊維強化樹脂複合材用ドリル
WO2015191034A1 (en) * 2014-06-09 2015-12-17 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
JP6719475B2 (ja) * 2015-09-04 2020-07-08 サントリーホールディングス株式会社 ウレアーゼ活性阻害剤
KR102109061B1 (ko) * 2015-09-10 2020-05-11 쟝쑤 애텀 바이오사이언스 앤드 파머수티컬 컴퍼니 리미티드 고요산혈증 또는 통풍을 치료 또는 예방하는 화합물
CN105675557B (zh) * 2016-01-07 2019-01-25 济南大学 基于苯炔荧光试剂检测硫脲含量的新方法
CA3030821C (en) 2016-07-18 2025-07-08 Arthrosi Therapeutics, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT OR PREVENTION OF A SYMPTOM ASSOCIATED WITH GOUT OR HYPEROURICEMIA
KR102597986B1 (ko) * 2017-04-28 2023-11-02 가부시키가이샤 후지야쿠힝 3-(3,5-디클로로-4-히드록시벤조일)-1,1-디옥소-2,3-디히드로-1,3-벤조티아졸의 결정형 및 염
CN109928890B (zh) * 2017-12-15 2021-11-09 重庆常捷医药有限公司 一种托伐普坦中间体2-甲基-4-n-(2-甲基苯甲酰)苯甲酸的制备方法
WO2020118114A1 (en) 2018-12-06 2020-06-11 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
SG11202105745UA (en) 2018-12-06 2021-06-29 Arthrosi Therapeutics Inc Crystalline forms of a compound for treating or preventing gout or hyperuricemia
CA3159300A1 (en) * 2019-12-09 2021-06-17 Tadashi Inoue Solid pharmaceutical preparation
CN111675675A (zh) * 2020-07-17 2020-09-18 苏州明锐医药科技有限公司 多替诺德的制备方法
CN111662247A (zh) * 2020-07-17 2020-09-15 苏州明锐医药科技有限公司 一种多替诺德的合成方法
CN112430221B (zh) * 2020-11-20 2023-06-23 成都诺和晟泰生物科技有限公司 用于预防、治疗或减轻高尿酸血症或痛风的化合物及其应用
WO2022169974A1 (en) 2021-02-05 2022-08-11 Nexys Therapeutics, Inc. Inhibitors of urat1 and pharmaceutical uses thereof
CN114903879B (zh) * 2022-06-23 2023-10-31 东北大学 3-烃基苯酚衍生物在制备预防或治疗高脂血症及相关代谢性疾病产品中的用途
CN115160314B (zh) * 2022-07-28 2023-12-05 南方医科大学 杂环芳酰胺类化合物及其制备方法和应用
WO2025085662A1 (en) 2023-10-17 2025-04-24 Vanderbilt University Compounds for tocolytic use
CN118580197A (zh) * 2023-11-16 2024-09-03 广东东阳光药业股份有限公司 一种多替诺雷制备方法及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3720683A (en) * 1970-09-02 1973-03-13 Squibb & Sons Inc 2-phenyl-3-acylbenzothiazolines and their oxides
EP1767531A4 (en) 2004-06-10 2011-01-05 Torii Pharmaceutical Co Ltd 6-HYDROXYBENZBROMARONE OR SALTING MEDICAL COMPOSITIONS CONTAINING THEREOF
JP3988832B2 (ja) 2004-11-29 2007-10-10 日本たばこ産業株式会社 窒素含有縮合環化合物及びその用途
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
EP1985297A1 (en) * 2006-01-27 2008-10-29 Japan Tobacco, Inc. Carboxylic acid compound and use thereof
US20080064871A1 (en) * 2006-05-26 2008-03-13 Japan Tobacco Inc. Production Method of Nitrogen-Containing Fused Ring Compounds
US20080305169A1 (en) * 2006-05-26 2008-12-11 Japan Tobacco Inc. Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
WO2008062740A1 (fr) * 2006-11-20 2008-05-29 Japan Tobacco Inc. Composé azoté à anneaux fusionnés et son utilisation

Also Published As

Publication number Publication date
JP5325065B2 (ja) 2013-10-23
ES2549603T3 (es) 2015-10-29
US8367843B2 (en) 2013-02-05
KR101647174B1 (ko) 2016-08-09
CA2775309A1 (en) 2011-04-07
EP2484669B1 (en) 2015-07-29
PT2484669E (pt) 2015-10-30
AU2010301675A1 (en) 2012-04-05
KR20120080183A (ko) 2012-07-16
PL2484669T3 (pl) 2015-12-31
NZ598582A (en) 2013-04-26
RU2536689C2 (ru) 2014-12-27
CN102639518A (zh) 2012-08-15
JP2011074017A (ja) 2011-04-14
BR112012007069B1 (pt) 2020-03-03
EP2484669A4 (en) 2013-02-27
AU2010301675B2 (en) 2013-08-22
WO2011040449A1 (ja) 2011-04-07
US20120184587A1 (en) 2012-07-19
DK2484669T3 (en) 2015-09-21
IL218519A0 (en) 2012-07-31
IN2012DN02551A (enExample) 2015-08-28
HK1169650A1 (en) 2013-02-01
ZA201201895B (en) 2013-09-25
CA2775309C (en) 2017-12-12
BR112012007069A2 (pt) 2016-04-19
PH12012500643A1 (en) 2012-11-12
IL218519A (en) 2016-03-31
HUE026007T2 (en) 2016-05-30
TWI461195B (zh) 2014-11-21
MX2012003392A (es) 2012-04-10
RU2012117786A (ru) 2013-11-10
EP2484669A1 (en) 2012-08-08
TW201121544A (en) 2011-07-01
MY160394A (en) 2017-03-15

Similar Documents

Publication Publication Date Title
CN102639518B (zh) 新型苯酚衍生物
CN104718213B (zh) 5,5‑杂芳族抗感染化合物
RU2733750C2 (ru) Производные карбоксизамещенных (гетеро)ароматических колец, способ их получения и применение
TW201117809A (en) Substituted amide compounds
TW200400027A (en) Compounds that modulate PPAR activity
JP2002509931A (ja) 置換されたインドールアルカノール酸
JPH11193281A (ja) アデノシンａ３受容体拮抗剤およびチアゾール化合物
WO2004080990A1 (ja) Ｃ－グリコシド誘導体又はその塩
WO2007097403A1 (ja) 消化管潰瘍治療又は予防薬
WO2007102515A1 (ja) フェニルチアゾール誘導体
EP1419770A1 (en) Apo ai expression accelerating agent
KR20100112623A (ko) 티아졸 유도체 및 ｖａｐ－１ 저해제로서 이의 용도
CN109996797A (zh) 作为乳酸脱氢酶的抑制剂的1h-吡唑-1-基-噻唑及其使用方法
JPWO2014104372A1 (ja) ハロゲン置換へテロ環化合物
RU2512547C2 (ru) Содержащее конденсированную кольцевую структуру производное и его применение в медицине
WO2014075618A1 (zh) 含有杂环的5-羟基吲哚类衍生物及其用途
AU767151B2 (en) Polycyclic thiazolidin-2-ylidene amines, method for the production and use thereof as medicaments
US20220289698A1 (en) Inhibitors of human atgl
WO2004060881A1 (ja) １，３−ベンゾチアジノン誘導体、その製造法および用途
HK1169650B (en) Novel phenol derivative
JPWO2007004733A1 (ja) ペルオキシソーム増殖剤活性化受容体δの活性化剤
WO2005095364A1 (ja) フェノキシ酢酸誘導体及びそれを用いた医薬
TW202321245A (zh) 用於治療的咪唑[1,2-b][1,2,4]三唑衍生物
WO2000044756A1 (en) Thiazolopyrimidine compounds, process for the preparation of the same and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1169650

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1169650

Country of ref document: HK